Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$0.20 CAD
Change Today 0.00 / 0.00%
Volume 0.0
RHA On Other Exchanges
Symbol
Exchange
Venture
OTC US
As of 2:22 PM 04/21/15 All times are local (Market data is delayed by at least 15 minutes).

annidis corp (RHA) Snapshot

Open
C$0.20
Previous Close
C$0.20
Day High
C$0.20
Day Low
C$0.20
52 Week High
06/13/14 - C$0.35
52 Week Low
03/19/15 - C$0.16
Market Cap
19.2M
Average Volume 10 Days
5.8K
EPS TTM
C$-0.06
Shares Outstanding
95.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ANNIDIS CORP (RHA)

Related News

No related news articles were found.

annidis corp (RHA) Related Businessweek News

No Related Businessweek News Found

annidis corp (RHA) Details

Annidis Corporation engages in the research, development, and sale of medical devices to eye-care professionals in the United States, Canada, and China. It offers RHA and RHA 2020-U Gold a multi-spectral imaging digital ophthalmoscope, which assists eye-care professionals in screening, diagnosing, and managing ocular diseases by allowing them to view non-invasively the deepest layers of the eye. Annidis Corporation was founded in 2007 and is based in Ottawa, Canada.

Founded in 2007

annidis corp (RHA) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: --
Founder, President and Director
Total Annual Compensation: C$102.0K
Chief Financial Officer
Total Annual Compensation: --
Compensation as of Fiscal Year 2013.

annidis corp (RHA) Key Developments

Annidis Corporation Announces Audited Consolidated Results for the Fourth Quarter and Full Year Ended December 31, 2014

Annidis Corporation announced audited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the three months period, revenue grew by 72.8% to CAD 552,838 compared to CAD 319,844 for the same period in 2013. Net loss was CAD 1,827,056 or CAD 0.02 per share compared to a loss of CAD 1,105,121 or CAD 0.01 per share for the same period in 2013. Net cash used in operating activities was CAD 1,469,617 compared to CAD 1,951,790 for the corresponding period in 2013. For the twelve months period, revenue grew by 121.6% to CAD 2,364,027 compared to CAD 1,066,807 for the same period in 2013. Net loss was CAD 5,672,756 or CAD 0.06 per share compared to a loss of CAD 4,308,582 or CAD 0.06 per share for the same period in 2013. Net cash used in operating activities was CAD 4,140,291 compared to CAD 3,993,044 for the corresponding period in 2013. The company’s annual revenue has significantly surpassed the previous full year performance of the company by 122% due to growing relationships with international customers.

Annidis Corporation Reports Unaudited Consolidated Earnings Results for the Third Quarter and Sales Results for the Nine Months Ended September 30, 2014

Annidis Corporation reported unaudited consolidated earnings results for the third quarter and sales results for the nine months ended September 30, 2014. For the quarter, the company's revenue was $480,218 compared to $255,096 for the same period in 2013. Net loss was $1,240,943 or $0.01 per share compared to a loss of $1,113,439 or $0.02 per share for the corresponding period in 2013. Cash used in operating activities was $475,239 compared to $765,908 for the corresponding period in 2013. For the nine months, the company's revenue was $1,811,189 compared to $746,963 for the same period in 2013.

Retinal Consultants of Arizona Adds Annidis RHA Instrument into its Patient-Based Offering Across the State of Arizona

Annidis Corporation announced that Retinal Consultants of Arizona has added Annidis RHA instrument into its patient-based offering across the state of Arizona. This partnership will allow RCA to continue its leadership in patient care by offering the best available technologies for examination and diagnosis of retinal eye diseases. The advantages of Annidis RHA include maximizing patient examinations, while reducing invasive tests and procedures to yield the same or better diagnostic quality. The RHATM instrument is a multi-spectral imaging digital ophthalmoscope that captures high-resolution image data through the retinal and sub retinal layers. Multi-spectral imaging extends the analysis eye care professionals use to distinguish between ocular structures. It both expands the examination wavelength range from green to invisible near infrared light and generates the probe wavelengths to separate specific spectral regions for enhanced visibility and discrimination. The combination of the images and extracted data points provides an enhanced view of the eye.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHA:CN C$0.20 CAD 0.00

RHA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RHA.
View Industry Companies
 

Industry Analysis

RHA

Industry Average

Valuation RHA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANNIDIS CORP, please visit www.annidis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.